These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18044094)

  • 1. Evaluation of PDE4 inhibition for COPD.
    Wang D; Cui X
    Int J Chron Obstruct Pulmon Dis; 2006; 1(4):373-9. PubMed ID: 18044094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 4 inhibitors for the treatment of COPD.
    Sturton G; Fitzgerald M
    Chest; 2002 May; 121(5 Suppl):192S-196S. PubMed ID: 12010850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
    Sanz MJ; Cortijo J; Morcillo EJ
    Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
    Lipworth BJ
    Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD.
    Liu A; Huang L; Wang Z; Luo Z; Mao F; Shan W; Xie J; Lai K; Li X
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1548-52. PubMed ID: 23375225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
    Rabe KF
    Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
    Gross NJ; Giembycz MA; Rennard SI
    COPD; 2010 Apr; 7(2):141-53. PubMed ID: 20397815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
    Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
    Giembycz MA; Field SK
    Drug Des Devel Ther; 2010 Jul; 4():147-58. PubMed ID: 20689641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic options in the management of COPD - focus on roflumilast.
    Antoniu SA
    Int J Chron Obstruct Pulmon Dis; 2011; 6():147-55. PubMed ID: 21468165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE4 inhibitors in COPD--a more selective approach to treatment.
    Vignola AM
    Respir Med; 2004 Jun; 98(6):495-503. PubMed ID: 15191033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
    Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
    Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease.
    Soto FJ; Hanania NA
    Curr Opin Pulm Med; 2005 Mar; 11(2):129-34. PubMed ID: 15699784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far.
    Giembycz MA
    Monaldi Arch Chest Dis; 2002 Feb; 57(1):48-64. PubMed ID: 12174704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roflumilast: clinical benefit in patients suffering from COPD.
    Ulrik CS; Calverley PM
    Clin Respir J; 2010 Oct; 4(4):197-201. PubMed ID: 20887341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.
    Kroegel C; Foerster M
    Expert Opin Investig Drugs; 2007 Jan; 16(1):109-24. PubMed ID: 17155857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma.
    Field SK
    Expert Opin Investig Drugs; 2008 May; 17(5):811-8. PubMed ID: 18447606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.